Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
CGCompugen Ltd. logo

Compugen Ltd. (CGEN)

NASDAQ Global Market · Currency in USD
$1.94 ▼ -0.02 (-1.02%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.94 ▲ +0.00 (+0.00%)
Pre-market: Oct 26, 4:00 AM ET

Summary

Previous Close
$1.96
Open
$1.97
Day's Range
$1.90 – $1.97
52 Week Range
$1.43 – $3.24
Volume
148,020
Avg. Volume
256,206
Market Cap
$183.76M
Beta (5Y Monthly)
2.79
PE Ratio (TTM)
5.17
EPS (TTM)
$0.37
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$5.00

Profile: Compugen Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
75
CEO
Eran Ophir
Website
cgen.com

Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.08 · Revenue est. $1.28M
DateEst.Actual
Aug 3, 2026-$0.08-$0.07Beat
May 18, 2026-$0.07-$0.08Miss
Mar 2, 2026-$0.07$0.60Beat
Nov 10, 2025-$0.09-$0.07Beat
Aug 6, 2025-$0.07-$0.08Miss
May 19, 2025-$0.06-$0.08Miss

Analyst view

Consensus price target
$5.00 ▲ +157.7%
Range $5.00 – $5.00
Rating: Buy
Buy 93% · Hold 0% · Sell 7%

Get free alerts on CGEN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.